Company news

Verrica Pharmaceuticals Inc. news in 2025

Verrica Pharmaceuticals Inc.'s news releases, calls and decks from 2025, newest first.

View company

Verrica Pharmaceuticals Announces Private Placement Financing of $50 Million to Retire Debt and Extend Cash Runway

November 24, 2025

Verrica Pharmaceuticals Reports Third Quarter 2025 Financial Results

November 14, 2025

Verrica Pharmaceuticals Presents New Data on VP-315 from its Phase 2 Clinical Trial in Basal Cell Carcinoma at the 40th Society for Immunotherapy of Cancer Annual Meeting

November 10, 2025

Verrica Pharmaceuticals Receives Positive Feedback from the European Medicines Agency (EMA) Supporting a Clear Regulatory Path Forward to File for Approval of YCANTH® in the European Union

October 20, 2025

Verrica Pharmaceuticals to Present New Data on VP-315 from its Phase 2 Trial in Basal Cell Carcinoma (BCC) at the 40th Society for Immunotherapy of Cancer (SITC) Annual Meeting

October 7, 2025

Verrica Pharmaceuticals Announces That Development Partner, Torii Pharmaceutical, Receives Approval for YCANTH® (TO-208) in Japan for the Treatment of Molluscum Contagiosum

September 19, 2025

Verrica Pharmaceuticals to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

September 2, 2025

Verrica Pharmaceuticals Reports Second Quarter 2025 Financial Results

August 12, 2025

Verrica Pharmaceuticals to Report Second Quarter 2025 Financial Results and Provide a Corporate Update on August 12, 2025

August 6, 2025

Verrica Pharmaceuticals Reports Strong Growth in YCANTH® Dispensed Applicator Units in 2Q 2025

July 9, 2025

Verrica Pharmaceuticals Announces Amendment to Collaboration and License Agreement with Torii Pharmaceutical to Launch Global Pivotal Phase 3 Clinical Trial to Study YCANTH® for the Treatment of Common Warts

July 1, 2025

Verrica Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference in New York

May 28, 2025

Verrica Pharmaceuticals Reports Quarterly 2025 Financial Results

May 13, 2025

Verrica Pharmaceuticals to Report First Quarter 2025 Financial Results and Provide a Corporate Update on May 13, 2025

May 7, 2025

Verrica Pharmaceuticals to Participate in the Citizens Life Sciences Conference in New York

April 30, 2025

Verrica Pharmaceuticals Reports Strong Demand-Led Growth in YCANTH® Dispensed Applicator Units in First Quarter 2025

April 7, 2025

Verrica Pharmaceuticals Appoints Gavin Corcoran, M.D. to its Board of Directors

April 2, 2025

Verrica Pharmaceuticals to Participate in the 24th Annual Needham Virtual Healthcare Conference

March 31, 2025

Verrica Pharmaceuticals Appoints Noah L. Rosenberg, M.D., as Chief Medical Officer

March 26, 2025

Verrica Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results

March 11, 2025

Verrica Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results and Provide a Corporate Update on March 11, 2025

March 3, 2025

Verrica Pharmaceuticals to Participate in the TD Cowen 45th Annual Health Care Conference in Boston

February 25, 2025

Verrica Pharmaceuticals Announces Presentation of Three Posters Featuring Positive Preliminary Topline Results of VP-315 for the Treatment of Basal Cell Carcinoma at the 2025 Winter Clinical Dermatology Conference

January 20, 2025

Calls in 2025